[Seungkwon Kim, Edaily Reporter] On July 29, South Korea’s domestic stock market continued to weaken, causing inverse exchange-traded funds (ETFs) tracking the KOSDAQ’s decline to dominate the list of top gainers. More than half of the top 30 highest-yielding funds that day were inverse tracking funds.

Amid widespread market losses, select biotech and healthcare stocks managed to rally, led by T&R Biofab and Lemon Healthcare. Both companies emerged as standout “counter-trend” performers, backed by strong first-half earnings improvements and a reassessment of their technological competitiveness.

◇ T&R Biofab Surges 7.2% as ECM Revenue Jumps 46% in H1

According to KG Zeroin MP Doctor, T&R Biofab closed at 2,525 KRW on July 29, up 7.2% from the previous trading day. The rally was driven by robust earnings expectations. The company reported consolidated first-half revenue of 18.3 billion KRW, representing a 46% year-over-year increase. Second-quarter revenue alone reached 9.5 billion KRW, up more than 10% from the previous quarter. Analysts attribute this rebound to a market reassessment of T&R Biofab’s undervalued regenerative medicine capabilities.

T&R Biofab is a regenerative medicine specialist primarily focused on 3D-printed biodegradable scaffolds. It has rapidly expanded into extracellular matrix (ECM)-based biosurgical products. Leveraging its decellularized ECM technology, the company offers a comprehensive portfolio that includes the composite hemostat “Hemofix,” the wound dressing “Reprofoam,” and acellular dermal matrix (ADM) products.

The biosurgical division served as the primary driver of earnings growth. Second-quarter standalone revenue rose 125% year-over-year and 35% quarter-over-quarter to 3.7 billion KRW. Annual ECM revenue surged from 1.4 billion KRW in 2024 to 3.6 billion KRW last year, followed by a 214.6% year-over-year jump to 1.3 billion KRW in Q1 2026. This top-line growth significantly narrowed the consolidated operating loss ratio from 60.1% in Q1 2025 to 10.7% in Q1 2026.

The company’s wholly-owned subsidiary, Bliss Pack, also strengthened its financial stability. Bliss Pack reported preliminary first-half revenue of 11.8 billion KRW, up 25% year-over-year, supported by strong ODM/OEM capabilities and a monthly production capacity of 4 million freeze-dried cosmetic balls.

The main driver for the second half of the year is pending approval from the U.S. Food and Drug Administration (FDA). T&R Biofab is seeking FDA clearance for its 3D-printed biodegradable scaffold “TnR CFI” (CranioFacial Implant) and recently submitted its final response to the agency’s request for supplemental information.

“We submitted the final response to the FDA’s request for supplemental information on July 1 and expect final approval after mid-August,” a company official stated. “Once approved, it will pave the way for our full-scale expansion into the U.S. and global markets.”

The company is simultaneously advancing its product pipeline. “We are preparing clinical trials for a medical-grade ECM-based skin booster aimed at a 2028 commercial launch, while also developing drug-eluting hydrogel devices,” the official added.

Kiwoom Securities analyst Oh Hyun-jin projected that T&R Biofab’s annual revenue would reach 46 billion KRW, a 65% year-over-year increase, driven by growth in its cosmetics business. In a separate report, Kiwoom set a target price of 4,800 KRW, forecasting an accelerated turnaround based on balance sheet stabilization and subsidiary growth.

◇ Lemon Healthcare Rises 6.2% as Medical Data Interoperability Technology Takes Center Stage

Lemon Healthcare closed the trading session at 4,120 KRW, up 6.2% from the previous day. The rise reflects renewed market attention on its flagship “Lemon Data Bridge” (LDB) technology following recent listing procedures. The company positions itself not merely as a system integration (SI) provider, but as a real-time, bidirectional medical data intermediary platform.

Data fragmentation across Electronic Medical Records (EMR) and Picture Archiving and Communication Systems (PACS)—compounded by closed medical IT environments—has long hindered the development of digital healthcare. Lemon Healthcare addressed this challenge through LDB, which integrates three core technologies: “Lemon Private” (standardizing APIs into JSON format), “QAB” (QueryAgentBox, enabling real-time data transfer in isolated hospital networks without altering legacy code), and “F-Flow” (an integrated platform operations framework).

Deployed across smart hospital services (LDB-H), electronic documents and certificates (LDB-E), and data relay services (LDB-D), LDB operates on a shared architecture that allows new hospitals to join simply by creating an account, without the need for additional custom development—a defining characteristic of Software-as-a-Service (SaaS). While its core competitive advantage stems from nearly a decade of operational integration across 130 hospitals, Lemon Healthcare also holds approximately 30 domestic and 10 international patents in the U.S., China, Japan, and Europe.

The company is also positioning itself as a key data provider for healthcare AI. Leveraging over 120 million consented medical records gathered through its “Claim of the Gods” app, Lemon Healthcare aims to supply standardized data to AI developers.

“The operational barrier we have built over 10 years across 130 hospitals cannot be easily replicated by capital alone,” said a Lemon Healthcare representative. “In the long term, this deep operational expertise will serve as the foundation that enables us to compete alongside tech giants.”